The Medicinal Chemistry of Chalcones as Anti-Mycobacterium tuberculosis Agents

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidad Nacional de Trujillo-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorRodríguez-Silva, Cristhian N.-
Autor(es): dc.creatorProkopczyk, Igor Muccilo-
Autor(es): dc.creatorDos Santos, Jean Leandro-
Data de aceite: dc.date.accessioned2025-08-21T18:02:50Z-
Data de disponibilização: dc.date.available2025-08-21T18:02:50Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2022-09-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.2174/1389557522666220214093606-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/245900-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/245900-
Descrição: dc.descriptionTuberculosis (TB), a highly fatal infectious disease, is caused by Mycobacterium tuberculosis (Mtb) that has inflicted mankind for several centuries. In 2019, the staggering number of new cases reached 10 million resulting in 1.2 million deaths. The emergence of multidrug-resistanceMycobacterium tuberculosis (MDR-TB) and extensively drug-resistant-Mycobacterium tuberculosis (XDR-TB) is a global concern that requires the search for novel, effective, and safer short-term therapies. Nowadays, among the few alternatives available to treat resistant-Mtb strains, the majority have limitations, which include drug-drug interactions, long-term treatment, and chronic induced toxicities. Therefore, it is mandatory to develop new anti-Mtb agents to achieve health policy goals to mitigate the disease by 2035. Among the several bioactive anti-Mtb compounds, chalcones have been described as the privileged scaffold useful for drug design. Overall, this review explores and analyzes 37 chalcones that exhibited anti-Mtb activity described in the literature up to April 2021 with minimum inhibitory concentration (MIC90) values inferior to 20 µM and selective index superior to 10. In addition, the correlation of some properties for most active compounds was evaluated, and the main targets for these compounds were discussed.-
Descrição: dc.descriptionFondo Nacional de Desarrollo Científico y Tecnológico-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionUnidad de Posgrado en Farmacia y Bioquímica Facultad de Farmacia y Bioquímica Universidad Nacional de Trujillo, Av. Juan Pablo II s/n-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionFAPESP: 2020/13279-7-
Descrição: dc.descriptionCNPq: 430172/2018-4-
Formato: dc.format2068-2080-
Idioma: dc.languageen-
Relação: dc.relationMini-Reviews in Medicinal Chemistry-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subject1,3-Diphenylpropenones-
Palavras-chave: dc.subjectantitubercular drugs-
Palavras-chave: dc.subjectchalcones-
Palavras-chave: dc.subjectchalconoids-
Palavras-chave: dc.subjectmedicinal chemistry-
Palavras-chave: dc.subjectMycobacterium tuberculosis H37Rv-
Palavras-chave: dc.subjectMycobacterium tuberculosis infection-
Palavras-chave: dc.subjectpharmaceutical design-
Título: dc.titleThe Medicinal Chemistry of Chalcones as Anti-Mycobacterium tuberculosis Agents-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.